Based on the putative NAFLD-promoting role of AHR, Xia et al. tested the AHR inhibitor alpha-naphthoflavone (ANF) as therapeutic regimen in HFD-fed mice. The gene discussed is AHR; the disease is metabolic dysfunction-associated steatotic liver disease.